Enhancement of endothelial progenitor cell numbers and migration by H1152, a Rho kinase specific inhibitor

Biosci Biotechnol Biochem. 2012;76(1):172-5. doi: 10.1271/bbb.110468. Epub 2012 Jan 7.

Abstract

Endothelial progenitor cells (EPCs) are applied in the treatment of ischemic diseases. In ex vivo culture of human cord-blood derived EPCs, H1152, (S)-(+)-2-methyl-1-[(4-methyl-5-iso-quinolinyl) sulfonyl]-homopiperazine, markedly increased the number of EPCs. It also induced EPC migration, stimulated the phosphorylation of AKT, and reduced the expression of p27 in the EPCs. Thus H1152 can be used effectively in ex vivo expansion of EPCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives*
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Cell Count
  • Cell Movement / drug effects*
  • Endothelial Cells / cytology*
  • Humans
  • Protein Kinase Inhibitors / pharmacology*
  • Stem Cells / cytology*
  • Stem Cells / drug effects*
  • Stem Cells / metabolism
  • rho-Associated Kinases / antagonists & inhibitors*

Substances

  • 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine
  • Protein Kinase Inhibitors
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases